Applications of human and bovine serum albumins in biomedical engineering: A review

Xu, Xinhao; Hu, Jinyu; Xue, Huaqian; Hu, Yingying; Liu, Ya-nan; Lin, Guanyang; Liu, Liangle; Xu, Ren-ai

doi:10.1016/j.ijbiomac.2023.126914

Cited by 37 publications

(7 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum albumin is the most abundant protein in plasma. Due to its extremely high biocompatibility, it is widely used as an excellent medicine-delivery carrier and plays an important role in nanodelivery systems. , This study selected BSA as it offers a competitive price advantage and is readily available and chose the desolvation method as the main preparation method.…”

Section: Results and Discussionmentioning

confidence: 99%

Albumin Nanoparticles Increase the Efficacy of Doxorubicin Hydrochloride Liposome Injection Based on Threshold Theory

Lin,

Li,

Qiu

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

One of the most significant reasons hindering the clinical translation of nanomedicines is the rapid clearance of intravenously injected nanoparticles by the mononuclear phagocyte system, particularly by Kupffer cells in the liver, leading to an inefficient delivery of nanomedicines for tumor treatment. The threshold theory suggests that the liver’s capacity to clear nanoparticles is limited, and a single high dose of nanoparticles can reduce the hepatic clearance efficiency, allowing more nanomedicines to reach tumor tissues and enhance therapeutic efficacy. Building upon this theory, researchers have conducted numerous validation studies based on the same nanoparticle carrier systems. These studies involve the use of albumin nanoparticles to improve the therapeutic efficacy of albumin nanomedicines as well as polyethylene glycol (PEG)-modified liposomal nanoparticles to enhance the efficacy of PEGylated liposomal nanomedicines. However, there is no research indicating the feasibility of the threshold theory when blank nanoparticles and nanomedicine belong to different nanoparticle carrier systems currently. In this study, we prepared two different sizes of albumin nanoparticles by using bovine serum albumin. We used the marketed nanomedicine liposomal doxorubicin hydrochloride injection (trade name: LIBOD, manufacturer: Shanghai Fudan-zhangjiang Biopharmaceutical Co., Ltd.), as the representative nanomedicine. Through in vivo experiments, we found that using threshold doses of albumin nanoparticles still can reduce the clearance rate of LIBOD, prolong its time in vivo, increase the area under the plasma concentration–time curve (AUC), and also lead to an increased accumulation of the drug at the tumor site. Furthermore, evaluation of in vivo efficacy and safety further indicates that threshold doses of 100 nm albumin nanoparticles can enhance the antitumor effect of LIBOD without causing harm to the animals. During the study, we found that the particle size of albumin nanoparticles influenced the in vivo distribution of the nanomedicine at the same threshold dose. Compared with 200 nm albumin nanoparticles, 100 nm albumin nanoparticles more effectively reduce the clearance efficiency of LIBOD and enhance nanomedicine accumulation at the tumor site, warranting further investigation. This study utilized albumin nanoparticles to reduce hepatic clearance efficiency and enhance the delivery efficiency of nonalbumin nanocarrier liposomal nanomedicine, providing a new avenue to improve the efficacy and clinical translation of nanomedicines with different carrier systems.

show abstract

Section: Results and Discussionmentioning

confidence: 99%

Albumin Nanoparticles Increase the Efficacy of Doxorubicin Hydrochloride Liposome Injection Based on Threshold Theory

Lin,

Li,

Qiu

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Many studies have verified this protein as a substance that can deliver drugs for malignant or inflammatory tissues. Importantly, albumin shows biodegradability and biocompatibility, significantly reducing the risk of immune reactions, and is meaningful considering its potential use as a drug carrier [190,191].…”

Section: Albumin-based Drug Carriersmentioning

confidence: 99%

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

Jamroży,

Kudłacik-Kramarczyk,

Drabczyk

et al. 2024

IJMS

View full text Add to dashboard Cite

Studies on bionanocomposite drug carriers are a key area in the field of active substance delivery, introducing innovative approaches to improve drug therapy. Such drug carriers play a crucial role in enhancing the bioavailability of active substances, affecting therapy efficiency and precision. The targeted delivery of drugs to the targeted sites of action and minimization of toxicity to the body is becoming possible through the use of these advanced carriers. Recent research has focused on bionanocomposite structures based on biopolymers, including lipids, polysaccharides, and proteins. This review paper is focused on the description of lipid-containing nanocomposite carriers (including liposomes, lipid emulsions, lipid nanoparticles, solid lipid nanoparticles, and nanostructured lipid carriers), polysaccharide-containing nanocomposite carriers (including alginate and cellulose), and protein-containing nanocomposite carriers (e.g., gelatin and albumin). It was demonstrated in many investigations that such carriers show the ability to load therapeutic substances efficiently and precisely control drug release. They also demonstrated desirable biocompatibility, which is a promising sign for their potential application in drug therapy. The development of bionanocomposite drug carriers indicates a novel approach to improving drug delivery processes, which has the potential to contribute to significant advances in the field of pharmacology, improving therapeutic efficacy while minimizing side effects.

show abstract

“…Proteins are important macromolecules for all forms of life as they influence cell metabolism, the immune system of living organisms, and perform other important bodily activities . Human serum albumin (HSA) is the most abundant protein in the human body and has many applications in medical fields such as replacing lost albumin in patients with hypoalbuminemia, treating hypovolemia, as a part of some diagnostic imaging kits, and as a supplement for cell culture. − HSA is one type of plasma-derived protein used for numerous therapies. In addition to HSA, there are other plasma proteins, such as globulins/immunoglobulins and fibrinogen, that are also used as therapies to treat a variety of diseases and medical conditions. − …”

Section: Introductionmentioning

confidence: 99%

Desalting Plasma Protein Solutions by Membrane Capacitive Deionization

Shrimant,

Kulkarni,

Hasan

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Plasma protein therapies are used by millions of people across the globe to treat a litany of diseases and serious medical conditions. One challenge in the manufacture of plasma protein therapies is the removal of salt ions (e.g., sodium, phosphate, and chloride) from the protein solution. The conventional approach to remove salt ions is the use of diafiltration membranes (e.g., tangential flow filtration) and ion-exchange chromatography. However, the ion-exchange resins within the chromatographic column as well as filtration membranes are subject to fouling by the plasma protein. In this work, we investigate the membrane capacitive deionization (MCDI) as an alternative separation platform for removing ions from plasma protein solutions with negligible protein loss. MCDI has been previously deployed for brackish water desalination, nutrient recovery, mineral recovery, and removal of pollutants from water. However, this is the first time this technique has been applied for removing 28% of ions (sodium, chloride, and phosphate) from human serum albumin solutions with less than 3% protein loss from the process stream. Furthermore, the MCDI experiments utilized highly conductive poly(phenylene alkylene)based ion exchange membranes (IEMs). These IEMs combined with ionomer-coated nylon meshes in the spacer channel ameliorate Ohmic resistances in MCDI improving the energy efficiency. Overall, we envision MCDI as an effective separation platform in biopharmaceutical manufacturing for deionizing plasma protein solutions and other pharmaceutical formulations without a loss of active pharmaceutical ingredients.

show abstract

Applications of human and bovine serum albumins in biomedical engineering: A review

Cited by 37 publications

References 187 publications

Albumin Nanoparticles Increase the Efficacy of Doxorubicin Hydrochloride Liposome Injection Based on Threshold Theory

Albumin Nanoparticles Increase the Efficacy of Doxorubicin Hydrochloride Liposome Injection Based on Threshold Theory

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

Desalting Plasma Protein Solutions by Membrane Capacitive Deionization

Contact Info

Product

Resources

About